Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Emergent BioSolutions to Release Fourth Quarter and Full Year 2015 Financial Results and Conduct a Conference Call on February 25, 2016
Globe Newswire

GAITHERSBURG, Md., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 25, 2016 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full twelve months of 2015, recent business developments, financial outlook for full year 2016, and revenue guidance for the first quarter of 2016.

This conference call can be accessed live by telephone or through Emergent’s website:

Live Teleconference Information:
Dial in number: (855) 766-6521
International dial in: (262) 912-6157
Passcode: 46021005
      Live Webcast Information:
      Visit emergentbiosolutions.com
      and select the “Investors” section

Pre-registering for the live call will expedite access and minimize hold times. You will be issued a passcode to bypass the operator and connect directly. To pre-register for the call, visit the following website: edge.media-server.com/m/p/9j5eeynk.

A replay of the call can be accessed on Emergent’s website emergentbiosolutions.com under “Investors.”

About Emergent BioSolutions Inc.
Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at emergentbiosolutions.com.

Follow us on twitter: @emergentbiosolu.

Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
BurrowsR@ebsi.com
 
Media Contact:
Tracey Schmitt Lintott
Vice President, Global Public Affairs 
and Corporate Responsibility
240-631-3394
SchmittT@ebsi.com

Primary Logo

 Top of page